According to this study, blockade of KIR2DL4/HLA-G signaling using specific antibodies or other immunomodulatory agents, might be possible to enhance the antitumor activity of immune cells and improve the efficacy of tumor immunotherapy. The gene discussed is KIR2DL4; the disease is neoplasm.